BackgroundTo characterize the clinico-pathological features including estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu (HER2) expression in breast cancers in Botswana, and to compare them by HIV status.MethodsThis was a retrospective study using data from the National Health Laboratory and Diagnofirm Medical Laboratory in Gaborone from January 1, 2011 to December 31, 2015. Clinico-pathological details of patients were abstracted from electronic medical records.ResultsA total of 384 unique breast cancer reports met our inclusion criteria. Of the patients with known HIV status, 42.7% (50/117) were HIV-infected. Median age at the time of breast cancer diagnosis was 54 years (IQR 44–66 years). HIV-infected individuals were more likely to be diagnosed before age 50 years compared to HIV-uninfected individuals (68.2% vs 23.8%, p < 0.001). The majority of patients (68.6%, 35/51) presented with stage III at diagnosis. Stage IV disease was not presented because of the lack of data in pathology records surveyed, and additionally these patients may not present to clinic if the disease is advanced. Overall, 68.9% (151/219) of tumors were ER+ or PR+ and 16.0% (35/219) were HER2+. ER+ or PR+ or both, and HER2- was the most prevalent profile (62.6%, 132/211), followed by triple negative (ER−/PR−/HER2-, 21.3%, 45/211), ER+ or PR+ or both, and HER2+, (9.0%, 19/211) and ER−/PR−/HER2+ (7.1%, 15/211). There was no significant difference in receptor status noted between HIV-infected and HIV-uninfected individuals.ConclusionsMajority of breast cancer patients in Botswana present with advanced disease (stage III) at diagnosis and hormone receptor positive disease. HIV-infected breast cancer patients tended to present at a younger age compared to HIV-uninfected patients. HIV status does not appear to be associated with the distribution of receptor status in breast cancers in Botswana.

中文翻译：

---

博茨瓦纳艾滋病毒感染者和未感染者乳腺癌临床病理特征的报告


背景描述博茨瓦纳乳腺癌中雌激素受体 (ER)、孕激素受体 (PR) 和 Her-2/neu (HER2) 表达等临床病理特征，并通过 HIV 状态对它们进行比较。方法这是一项使用数据的回顾性研究2011 年 1 月 1 日至 2015 年 12 月 31 日，来自哈博罗内国家卫生实验室和诊断医学实验室的数据。患者的临床病理详细信息是从电子病历中提取的。结果共有 384 份独特的乳腺癌报告符合我们的纳入标准。在已知 HIV 状况的患者中，42.7% (50/117) 感染了 HIV。诊断乳腺癌时的中位年龄为 54 岁（IQR 44-66 岁）。与未感染 HIV 的个体相比，HIV 感染者在 50 岁之前被诊断的可能性更高（68.2% vs 23.8%，p < 0.001）。大多数患者（68.6%，35/51）在诊断时处于 III 期。由于所调查的病理记录中缺乏数据，因此没有出现 IV 期疾病，此外，如果疾病进展，这些患者可能不会到诊所就诊。总体而言，68.9% (151/219) 的肿瘤为 ER+ 或 PR+，16.0% (35/219) 为 HER2+。 ER+ 或 PR+ 或两者兼而有之，HER2- 是最常见的谱型 (62.6%, 132/211)，其次是三阴性 (ER−/PR−/HER2-, 21.3%, 45/211)、ER+ 或 PR+ 或两者和 HER2+（9.0%，19/211）和 ER−/PR−/HER2+（7.1%，15/211）。 HIV 感染者和 HIV 未感染者之间的受体状态没有显着差异。 结论 博茨瓦纳的大多数乳腺癌患者在诊断时处于晚期疾病（III 期）且激素受体呈阳性。与未感染艾滋病毒的患者相比，感染艾滋病毒的乳腺癌患者往往发病年龄更年轻。 在博茨瓦纳，艾滋病毒状况似乎与乳腺癌受体状况的分布无关。